Hovione Licenses Inhaler Technology for Influenza Drug to Sankyo & Biota

Hovione recently announced the signature of an agreement in which Sankyo Company Ldt. and Biota Holding Ltd. have jointly licensed Hovione's dry powder inhaler technology for the delivery of long-acting neuraminidase inhibitors (LANI) owned by Sankyo and Biota, which are active against the influenza virus.

Drug Delivery Technology, vol. 7, no. 4